RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR EXPRESSING THE HUMAN ALPHA-1-ANTITRYPSIN GENE

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
231	Alpha-1-antitrypsin deficiency	2

231. Alpha-1-antitrypsin deficiency

Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000602-30-SE (EUCTR)	29/06/2020	24/04/2020	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate theEfficacy ...	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate theEfficacy ...	Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limit ...	Product Name: Kamada -AAT for Inhalation or inhaled AAT (AAT) INN or Proposed INN: Alpha-1 Antitrypsi ...	Kamada Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Argentina;Finland;Belgium;Ireland;Netherlands;United Kingdom;Italy;Sweden
2	EUCTR2019-000602-30-NL (EUCTR)	30/09/2019	15/05/2019	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate theEfficacy ...	A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate theEfficacy ...	Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limit ...	Product Name: Kamada -AAT for Inhalation or inhaled AAT (AAT) INN or Proposed INN: Alpha-1 Antitrypsi ...	Kamada Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 3	Finland;Belgium;Ireland;Netherlands;United Kingdom;Sweden

First Previous1Next Last